Haematological studies on90Sr-90Y-toxicity: II. Femoral CFU-s kinetics and mitogen response of spleen cells

Stevenson, A. F. G.; Daculsi, Richard; Mönig, H.

doi:10.1007/bf01323753

Cited by 4 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, compared to beta emitters, the toxic effects on hematopoiesis are less frequent with 223 Ra [ 9 ]. It has been published that radiotherapy with beta and gamma isotopes induces numerical and also functional changes in leukocytes [ 11 , 12 , 13 , 14 , 15 ]. In line with only mild effects of 223 Ra, our group showed that in eleven patients with metastasized, castration-resistant prostate cancer one cycle of treatment with this alpha-emitter did not significantly impair lymphocyte function in vitro [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer

Barsegian,

Möckel,

Buehler

et al. 2024

Cancers

View full text Add to dashboard Cite

Previous data indicate that one cycle of treatment with radium-223 (223Ra) did not significantly impair lymphocyte function in patients with metastasized, castration-resistant prostate cancer. The aim of the current study was to assess in 21 patients whether six cycles of this therapy had an effect on lymphocyte proliferation and interferon-γ and interleukin (IL)-10 ELISpot results. Lymphocyte proliferation after stimulation with microbial antigens and the production of interferon-γ continuously decreased after six cycles of radionuclide therapy, reaching statistical significance (p < 0.05) at months 1, 2, 4, and/or 6 after therapy. One month after the last cycle of therapy, 67% of patients showed a decrease in tumor burden. The tumor burden correlated negatively with IL-10 secretion at baseline, e.g., after stimulation with tetanus antigen (p < 0.0001, r = −0.82). As determined by receiver operating characteristic (ROC) curve analysis, tetanus-specific IL-10 spots at baseline had the highest predictive value (p = 0.005) for tumor burden at month 6, with an area under the curve (AUC) of 0.90 (sensitivity 100%, specificity 78%). In conclusion, we observed an additive effect of treatment with 223Ra on immune function and found that IL-10 secretion at baseline predicted tumor burden at month 6 after treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer

Barsegian,

Möckel,

Buehler

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer

Barsegian

Möckel

Horn

et al. 2016

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

Impairment of lymphocyte function following yttrium-90 DOTATOC therapy

Barsegian

Hueben²,

Müeller³

et al. 2015

Cancer Immunol Immunother

View full text Add to dashboard Cite

The radiolabeled somatostatin analogue, yttrium-90 DOTA-D-Phe(1)-Tyr(3)-octreotide (DOTATOC), is currently applied to treat advanced somatostatin receptor-positive tumors, e.g., neuroendocrine tumors of the pancreas, lung or gut. However, effects of this treatment on antimicrobial immune responses are not yet defined. In 20 patients treated with DOTATOC, cellular in vitro immune function was determined. Their antimicrobial lymphocyte responses were assessed by lymphocyte transformation test and enzyme-linked immunospot-measuring lymphocyte proliferation and on a single cell level production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10)-prior to therapy, at day 1, day 7 and day 90 post-therapy. Proliferative lymphocyte responses and interferon-γ production after in vitro stimulation with microbial antigens were non-significantly suppressed at day 1 and significantly (p < 0.05) at day 7 versus pre-therapy. In vitro immune responses did not fully recover until day 90. In contrast, at day 1 interleukin-10 production was significantly (p < 0.05) increased. Taken together, we observed a decrease in pro-inflammatory immune responses after DOTATOC therapy. Patients with versus without bone metastases displayed significantly (p < 0.05) lower cellular immune responses toward several microbial antigens. Progressive disease and higher tumor burden could also be defined as factors associated with impaired immune function. Spearman correlation analysis indicated that cellular in vitro immunity was positively correlated with kidney function; better kidney function led to stronger immune responses. In conclusion, DOTATOC therapy caused a decrease in in vitro immune responses against microorganisms. The clinical impact needs to be evaluated in further studies.

show abstract

Haematological studies on90Sr-90Y-toxicity: II. Femoral CFU-s kinetics and mitogen response of spleen cells

Cited by 4 publications

References 15 publications

Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer

Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer

Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer

Impairment of lymphocyte function following yttrium-90 DOTATOC therapy

Contact Info

Product

Resources

About